07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Accurexa, DelMar Pharma deal

DelMar and Accurexa partnered to develop Accurexa’s ACX-31 implantable polymer wafer to locally deliver DelMar’s VAL-083 in combination with temozolomide and/or carmustine to treat brain cancer and other solid tumors. The partners will share undisclosed...
07:00 , Apr 10, 2014 |  BC Innovations  |  Targets & Mechanisms

Catastrophic vacuolization

Karolinska Institute scientists have found a way to attack glioblastoma multiforme-one of the most deadly forms of brain cancer-by inducing an unconventional cell death pathway that triggers catastrophic vacuolization.1 The team identified a small molecule...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Guilford regulatory update

U.S. Patent No. 5,626,862 issued to Massachusetts Institute of Technology (Cambridge, Mass.) and Johns Hopkins University (Baltimore, Md.) covering controlled local delivery of chemotherapeutic agents to treat solid tumors. GLFD has an exclusive license to...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Arbor Pharmaceuticals, Eisai sales and marketing update

Eisai divested U.S. rights to its Gliadel Wafer implants to Arbor. The biodegradable polymer implant containing carmustine is approved as an adjunct to surgery and radiation in patients with newly diagnosed high-grade malignant glioma...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Bristol-Myers sales and marketing update

Bristol-Myers said it recalled 10 lots of 50 mg/mL vials of 100 mg BiCNU carmustine after a routine inspection at the former manufacturing facility revealed an overfilled vial. The recall affects lots manufactured by...
07:00 , May 30, 2011 |  BC Week In Review  |  Clinical News

Gliadel Wafer carmustine implant: Phase II data

An open-label, U.S. Phase II trial in 59 evaluable patients with 1-3 brain metastases showed that Gliadel Wafer implants placed into the surgical cavity following tumor resection significantly improved memory from baseline at 6 and...
07:00 , Jun 8, 2009 |  BioCentury  |  Finance

Managing Austerity

In its first review of European biotech finance in 1999, BioCentury noted that the industry faced the potential dilemma of having too many clinical programs and not enough capital to finance their development. The first...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

Trabedersen: Phase III started

Antisense began the open-label, active-controlled, international Phase III SAPPHIRE trial to compare 10 µM of intratumoral trabedersen given every other week vs. standard chemotherapy with temozolomide or carmustine in about 130 patients. Antisense Pharma GmbH,...
07:00 , Apr 6, 2009 |  BioCentury  |  Regulation

Avastin's quality of life

Even though an FDA panel voted unanimously last week that the objective response rates in Phase II trials of Avastin bevacizumab to treat glioblastoma multiforme are reasonably likely to predict clinical benefit for the purpose...
08:00 , Dec 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer...